Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,099 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioavailability Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

NCT06003465
View directory record Official record
Conditions
Healthy
Interventions
LY3437943, Test, Reference
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Oral Bioavailability of Remimazolam

NCT04113564
View directory record Official record
Conditions
Bioavailability
Interventions
Remimazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

NCT01506544
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

NCT01582399
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Pharmacodynamics of ASKP1240, Healthy Volunteers
Interventions
ASKP1240
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

NCT01114854
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate IR, Topiramate ER
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • National City, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

NCT01899105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
lumacaftor, ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

NCT00988624
View directory record Official record
Conditions
Alzheimer's Disease, Huntington Disease
Interventions
Dimebon IR Tablet, Dimebon MR1, Dimebon MR2, Dimebon MR3, Dimebon MR4
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 27, 2026, 10:56 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 27, 2026, 10:56 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG06474 in Healthy Young Participants

NCT05943327
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel

NCT01202799
View directory record Official record
Conditions
Pain
Interventions
2% w/w diclofenac sodium topical gel, 1.5% w/w diclofenac sodium topical solution, 75 mg diclofenac sodium delayed release tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

NCT04128787
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

NCT07413133
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

NCT05923411
View directory record Official record
Conditions
Healthy Participants
Interventions
Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

The Effect of Stomach Acid on Foscarnet

NCT00000964
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 27, 2026, 10:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation

NCT00731562
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability, Smoking Cessation
Interventions
Varenicline Tartrate Controlled Release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 27, 2026, 10:56 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules

NCT05802797
View directory record Official record
Conditions
Healthy Diet
Interventions
Algae Oil Fortified Soymilk, Algae Oil Capsule
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

NCT06916065
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide and Tirzepatide, Eloralintide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

NCT05467696
View directory record Official record
Conditions
Health Volunteers
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ribavirin 200 mg Tablets Under Fasting Conditions

NCT00835146
View directory record Official record
Conditions
Healthy
Interventions
Ribavirin 200 mg tablets, COPEGUS™
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
View directory record Official record
Conditions
Healthy Subjects
Interventions
Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 27, 2026, 10:56 AM EDT